Trial Profile

A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Losartan (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use

Most Recent Events

21 Jan 2023 Results comparig the R0 resection rate on each of Arms 2 and 3 independently versus Arm 1 at a one-sided 0.10 level in borderline resectable and locally advanced pancreatic ductal adenocarcinoma presented at the 2023 Gastrointestinal Cancers Symposium
07 Sep 2022 Planned End Date changed from 31 Dec 2025 to 1 Jun 2027.
07 Sep 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com